<DOC>
	<DOCNO>NCT01890694</DOCNO>
	<brief_summary>Hyponatremia condition low sodium level blood . Individuals cirrhosis may develop low blood sodium complication liver disease . In patient , presence low blood sodium may exacerbate complication encephalopathy , result confusion , drowsiness , coma . It may also affect ability body fight infection . In certain case , cirrhotic patient may hospitalize treatment low blood sodium . The drug tolvaptan currently FDA approve treatment hyponatremia patient cirrhosis . Although show increase sodium level , clinical trial lead approval otherwise assess clinical benefit drug . This study design determine whether patient cirrhosis derive clinical benefit receive tolvaptan treatment hyponatremia within 2 day admission . Specifically , whether associate shorten length stay improvement complication cirrhosis .</brief_summary>
	<brief_title>Tolvaptan Reduce Length Stay Hospitalized Patients With Cirrhosis Hyponatremia</brief_title>
	<detailed_description>As per hyponatremia standard treatment care , patient consider study diuretic therapy discontinue least 1 day prior screen visit receive volume expansion 25 % salt poor albumin , clinically indicated ensure adequate intravascular volume expansion standard care patient hospitalize complication cirrhosis . Patients approach present write consent form first 24 hour admission NYUMC ( Tisch Hospital ) . They verbally inform purpose procedure study , well potential risk benefit . Following write consent , patient undergo series screening procedure , include physical examination , medical history , blood work , hepatic encephalopathy assessment , determine eligibility . After screen determination patient fulfill inclusion exclusion criterion , patient randomize following day Day 0 receive oral tolvaptan placebo daily . Patients treatment arm receive oral tolvaptan initial dose 15mg daily . The placebo arm use comparison group determine whether long-term , ambulatory tolvaptan administration associate clinical benefit patient cirrhosis hyponatremia . Patients placebo arm receive current standard treatment patient cirrhosis hyponatremia . Current standard treatment hyponatremia cirrhotic patient involve fluid restriction diet ( 1L fluid daily ) , discontinuation diuretic therapy ( furosemide , spironolactone ) , frequent monitoring sodium level . Severe hyponatremia ( Na &lt; 120mEq/L ) involve infusion hypertonic saline . Patients encourage drink response thirst , patient re-evaluated 8 hour determination Na level first dose . If serum sodium concentration remain 136 mEq/L increase less 5 mEq/L prior 24 hour , dose increase 15mg maximum dose 30mg . Too rapid correction serum sodium define either 8 mEq/L first 8 hour great 12mEq/L 24 hour . In situation , tolvaptan either withheld decrease next dose patient instructed increase fluid intake . Similar adjustment make serum sodium concentration rise 145mEq/L . Patients undergo physical examination laboratory evaluation include electrolyte , BUN/Cr , liver test determination reason continue hospitalization per standard care Day 1 8 day discharge discharge occurs prior Day 8 . Neutrophil function assay obtain upon randomization week 4 discharge . Urine electrolytes renin copeptin level obtain Day 0 , Day 8 ( still hospitalize ) , day discharge , monthly . Patients undergo detailed assessment hepatic encephalopathy Days 0 , 2 , 4 , 8 day discharge occur prior Day 8 . Patients also complete assessment day discharge occur Day 8 . Quality life questionnaire complete Day 0 , Day 8 ( optional ) , day discharge ( optional ) , weekly first month monthly total 3 month discharge . In addition , patient ask complete questionnaire follow-up visit , occur 1 , 2 , 4 week study drug discontinuation . Patients clinically significant fluid overload ( moderate ascites , grade 1 edema ) , Na level 130 great , asterixis present , severe azotemia present ( BUN less 30mg/dl , Cr le 1.5mg/dl ) start spironolactone 50mg daily furosemide 20mg daily . Doses increase 50mg 20mg , respectively , daily every week clinically significant fluid overload persist , weight loss previous week le 5 lb , safety assessment remain satisfied . Diuretic dos either reduced hold excessive fluid loss ( 10 lbs previous week ) one safety parameter present . At discharge , patient continue Study Drug weekly visit one month monthly , discharge , 3 month . At visit , patient interim history ( need hospitalization ) , performance large volume paracentesis volume ascites remove , physical examination , liver kidney test , assessment hepatic encephalopathy . Following discontinuation study drug , patient ask come clinic follow-up visit week 1 , 2 , 4 , post-discontinuation study drug . At visit , patient interim history ( need hospitalization ) , performance large volume paracentesis volume ascites remove , physical examination , liver kidney test , assessment hepatic encephalopathy .</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Cirrhosis Screening within 24 hour admission Na level le 130mEq/L Presence fluid overload either history ascites edema Cr &lt; 2.0mg/dl Planned length stay randomization least 24 hour Anticipated survival least 8 day Ability provide inform consent Hospitalization great 24 hour screen Depletional hyponatremia Hyponatremia due hyperglycemia Acute transient hyponatremia associate head trauma postoperative state Hyponatremia due primary polydipsia , adrenal insufficiency , hypothyroidism Urgent need treatment hyponatremia saline hypertonic saline Treatment demeclocycline , lithium chloride , urea Cr great 2.0mg/dl Stage 3 4 hepatic encephalopathy Inability provide inform consent Planned discharge within 24 hour Anticipated survival le 8 day GI bleed within one month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hyponatremia</keyword>
	<keyword>Dilutional Hyponatremia</keyword>
	<keyword>Euvolemic Hyponatremia</keyword>
	<keyword>Hypervolemic Hyponatremia</keyword>
	<keyword>Fluid Restriction</keyword>
	<keyword>Tolvaptan</keyword>
</DOC>